Recent advances in immunotherapy have transformed the treatment landscape for multiple myeloma, providing new hope for patients with relapsed or refractory disease. These innovative therapies are attracting significant attention within the myeloma community due to their potential to achieve deep and durable responses.
Today, three major categories of immunotherapy are reshaping the management of multiple myeloma:
- CAR-T Cell Therapy
- Antibody-Drug Conjugates (ADCs)
- Bispecific Antibodies
Each approach works differently and offers unique benefits and challenges.
CAR-T Cell Therapy
CAR-T cell therapy is widely regarded as one of the most powerful immunotherapies currently available for multiple myeloma. The treatment involves collecting a patient’s T cells, genetically engineering them in a laboratory to recognize and attack myeloma cells, and then infusing them back into the patient.
Most approved CAR-T therapies for multiple myeloma target B-cell maturation antigen (BCMA), a protein commonly expressed on myeloma cells.
Several BCMA-targeted CAR-T therapies have been approved in China for adult patients with relapsed or refractory multiple myeloma who have received multiple prior lines of treatment, including a proteasome inhibitor and an immunomodulatory agent.
One of the key advantages of CAR-T cell therapy is that it is typically a one-time treatment. After cell collection, manufacturing, and a single infusion, many patients can achieve deep responses and may remain free from additional anti-cancer treatment for an extended period. This potential for long-lasting remission is one of the reasons CAR-T therapy has generated such excitement.
However, CAR-T therapy is highly specialized and is currently available only at selected medical centers with the necessary expertise and infrastructure.
Antibody-Drug Conjugates (ADCs)
Antibody-drug conjugates combine the targeting ability of antibodies with the cancer-killing power of chemotherapy. These therapies deliver anti-cancer drugs directly to myeloma cells, helping to improve precision while reducing damage to healthy tissues.
A leading example is belantamab mafodotin (Blenrep), a BCMA-targeted ADC that has been approved in China for multiple myeloma.
Unlike CAR-T therapy, ADCs require ongoing treatment rather than a single administration. Patients may need dose adjustments during treatment to manage side effects. One of the most important adverse effects associated with belantamab mafodotin is corneal toxicity, which requires regular eye monitoring and may necessitate changes in dosing schedules.
Bispecific Antibodies
Bispecific antibodies represent another promising breakthrough in multiple myeloma treatment. These engineered antibodies are designed to bind simultaneously to myeloma cells and immune cells, particularly T cells. By bringing the immune system into direct contact with cancer cells, bispecific antibodies help trigger a targeted anti-tumor response.
Several bispecific antibodies targeting BCMA have already been approved, while additional candidates are being evaluated in ongoing clinical studies.
A major advantage of bispecific antibodies is their broader accessibility compared with CAR-T therapy. They are administered as ongoing treatment and can also be combined with other anti-myeloma therapies, offering flexibility in treatment planning.
Expanding Treatment Options for Multiple Myeloma
The emergence of CAR-T cell therapy, ADCs, and bispecific antibodies has created a powerful immunotherapy arsenal against multiple myeloma. These innovative treatments are providing patients with more options than ever before and are helping to improve outcomes for individuals whose disease has relapsed or become resistant to conventional therapies.
As research continues to advance, immunotherapy is expected to play an increasingly important role in the future of multiple myeloma treatment.
